Drug Combo Proves Powerful Against Lung Cancer Glens Falls NY

A two-drug combination treatment in Glens Falls proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Christopher Dolinsky
(518) 926-6670
100 Park St
Glens Falls, NY
MICHAEL KEEFE, MD
(518) 226-6000
3 Care Lane
Saratoga Springs, NY
Aqeel Abbas Gillani, MD
518-926-6700
Pruyn Pavillion 102 Park St
Saratoga Springs, NY
Robert William Sponzo, MD
518-926-6700
102 Park St Pruyn Pavilion
Glens Falls, NY
Dae Chol Koh, MD
518-793-1342
428 Glen St
Glens Falls, NY
Michael E Keefe
(518) 226-6000
3 Care Ln
Saratoga Springs, NY
DARCI GAIOTTI, MD
(518) 926-6620
102 Park Street
Glens Falls, NY
EDWARD LIEBERS, MD
(518) 226-6000
3 Care Lane
Saratoga Springs, NY
David Matthew Mastrianni, MD
518-226-6000
1 West Ave Ste 300
Saratoga Springs, NY
Elizabeth Anne Valentine, MD
518-399-4600
15 Evergreen Dr
Saratoga Springs, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Exercise for Breast Cancer Survival Glens Falls NY
Breast cancer is a physically and emotionally traumatizing disease. A study underrtaken at the Harvard School of Public Health examined four observational studies to determine whether physical activity could improve quality of life after a breast cancer diagnosis and on increased breast cancer survival.
- Hormone Therapy for Breast Cancer Glens Falls NY
- Exercise for Prostate Cancer Glens Falls NY
- Genetic Clues for Skin Cancer Therapies Glens Falls NY
- Risks for Childhood Cancer Survivors Glens Falls NY
- Side Effect Of Chemotherapy Drugs Glens Falls NY
- Hormone Therapy for Lung Cancer Glens Falls NY
- Delayed Prostate Cancer Therapy Glens Falls NY
- Fungal Infection Treatments Glens Falls NY